Cornerstone Therapeutics Announces Management Change

CARY, N.C., April 7 /PRNewswire-FirstCall/ -- Cornerstone Therapeutics Inc.
(Nasdaq: CRTX), a specialty pharmaceutical company focused on acquiring,
developing and commercializing significant products primarily for the
respiratory market, today announced the resignation of Chenyqua Baldwin, Vice
President, Finance, and Chief Accounting Officer. The Company has already
begun a search for a successor.

"I would like to thank Chenyqua for her significant contributions to
Cornerstone over the past five years," said Craig A. Collard, Cornerstone's
President and Chief Executive Officer. "Chenyqua has been an integral part of
the growth of the Company to date and we wish her success as she moves on to
new challenges."

About Cornerstone Therapeutics
Cornerstone Therapeutics Inc. (Nasdaq: CRTX), headquartered in Cary, N.C., is
a specialty pharmaceutical company focused on acquiring, developing and
commercializing products primarily for the respiratory and related markets.
The Company currently promotes multiple marketed products in the United States
to respiratory-focused physicians and key retail pharmacies with its specialty
sales force. The Company also has a late-stage clinical pipeline with five
regulatory approval submissions targeted within the next three years. Key
elements of the Company's strategy are to in-license or acquire rights to
underpromoted, patent-protected, branded respiratory or related pharmaceutical
products, or late-stage product candidates; implement life cycle management
strategies to maximize the potential value and competitive position of the
Company's currently marketed products, newly acquired products and product
candidates that are currently in development; grow product revenue through the
Company's specialty sales force which is focused on the respiratory and
related markets; and maintain and strengthen the intellectual property
position of the Company's currently marketed products, newly acquired products
and product candidates.

Safe Harbor Statement
Statements in this press release regarding the progress and timing of our
product development programs and related trials; our future opportunities; our
strategy, future operations, financial position, future revenues and projected
costs; our management's prospects, plans and objectives; and any other
statements about management's future expectations, beliefs, goals, plans or
prospects constitute forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Any statements that are not
statements of historical fact (including, without limitation, statements
containing the words "anticipate," "believe," "could," "estimate," "expect,"
"plan," "should," "target," "will," "would," and similar expressions) should
also be considered to be forward-looking statements.

There are a number of important factors that could cause our actual results or
events to differ materially from those indicated by such forward-looking
statements, including risks relating to our ability to develop and maintain
the necessary sales, marketing, supply chain, distribution and manufacturing
capabilities to commercialize our products, including difficulties relating to
the manufacture of ZYFLO CR(R) tablets; the possibility that the Food and Drug
Administration (the FDA) will take enforcement action against us or one or
more of our marketed drugs which do not have FDA-approved marketing
applications; patient, physician and third-party payor acceptance of our
products as safe and effective therapeutic products; our ability to maintain
regulatory approvals to market and sell our products that do have FDA approved
marketing applications; our ability to enter into additional strategic
licensing, collaboration or co-promotion transactions on favorable terms, if
at all; our ability to maintain compliance with NASDAQ listing requirements;
adverse side effects experienced by patients taking our products; difficulties
relating to clinical trials, including difficulties or delays in the
completion of patient enrollment, data collection or data analysis; the
results of preclinical studies and clinical trials with respect to our
products under development and whether such results will be indicative of
results obtained in later clinical trials; our ability to satisfy FDA and
other regulatory requirements; our ability to obtain, maintain and enforce
patent and other intellectual property protection for our products and product
candidates; and the other factors described in our Annual Report on Form 10-K
filed with the Securities and Exchange Commission (the SEC) on March 26, 2009,
in the section entitled "Item 1A. Risk Factors" and other filings that we make
with the SEC. If one or more of these factors materialize, or if any
underlying assumptions prove incorrect, our actual results, performance or
achievements may vary materially from any future results, performance or
achievements expressed or implied by these forward-looking statements.

In addition, the statements in this press release reflect our expectations and
beliefs as of the date of this release. We anticipate that subsequent events
and developments will cause our expectations and beliefs to change. However,
while we may elect to update these forward-looking statements publicly at some
point in the future, we specifically disclaim any obligation to do so, whether
as a result of new information, future events or otherwise. Our
forward-looking statements do not reflect the potential impact of any future
acquisitions, mergers, dispositions, business development transactions, joint
ventures or investments that we may make. These forward-looking statements
should not be relied upon as representing our views as of any date after the
date of this release.

ZYFLO CR(R) is a trademark of Cornerstone Therapeutics Inc.

Investor Relations Contacts:
FD
Evan Smith/Brian Ritchie
212-850-5600
evan.smith@fd.com/brian.ritchie@fd.com

Media Relations Contact:
FD
Robert Stanislaro
212-850-5600
robert.stanislaro@fd.com

SOURCE Cornerstone Therapeutics Inc.

Investor Relations Contacts, Evan Smith, evan.smith@fd.com, or Brian Ritchie,
brian.ritchie@fd.com, both of FD, +1-212-850-5600, or Media Relations Contact,
Robert Stanislaro of FD, robert.stanislaro@fd.com, or +1-212-850-5600